The demand for plant derived analgesics in USA is projected to grow from USD 1.5 billion in 2025 to USD 2.9 billion by 2035, at a CAGR of 6.8%. Morphine will dominate with a 31.0% market share, while tablets will lead the formulation type segment with a 40.4% share.